Disease-Vaccine-Landing-Page

Both RotaTeq and ROTARIX are live virus vaccines and it is possible for a vaccine recipient to shed the vaccine-strain virus to others. Persons most at risk for developing rotavirus...

In the U.S., researchers have reported that rotavirus vaccines have decreased the number of rotavirus infections requiring medical attention. However, researchers also note that since vaccine’s introduction, the G12P[8] rotavirus...

According to the package insert2, from infancy through one year, ROTARIX efficacy against severe rotavirus gastroenteritis was 84.7 percent in infants who received two vaccine doses, and 81 percent among...

According to the package insert1, RotaTeq vaccine will prevent about 74 percent of rotavirus cases, about 98 percent of severe cases, and about 96 percent of hospitalizations due to rotavirus.No...

On June 11, 2010, the CDC issued revised recommendations and added severe combined immunodeficiency (SCID) as a contraindication to receiving rotavirus vaccines. SCID is a group of rare disorders caused...

On March 22, 2010, the FDA announced that an independent U.S. academic research team had found DNA from porcine circovirus 1 (PCV1) in the ROTARIX vaccine. The FDA recommended that...

Contraindications to receiving rotavirus vaccines included a history of severe allergic reaction to a previous vaccine dose or to any component of the vaccine. ROTARIX was not recommended for infants...

On April 3, 2008, the FDA approved ROTARIX, a second live oral rotavirus vaccine for use in infants six through 24 weeks of age. Manufactured by GlaxoSmithKline, this vaccine was...

The CDC’s ACIP, which had begun discussions on RotaTeq in 2005, voted in February 2006 for all infants to receive 3 vaccine doses at 2, 4, and 6 months of...

Wyeth-Lederle was not the only pharmaceutical company working on a rotavirus in the 1990s. Both Merck and GlaxoSmithKline were actively in the development stages of a vaccine. On February 3,...